Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Correction for Baker et al., Clin Cancer Res 14 (7) 2171-2179.
Clinical Cancer Research 14, 2893, May 1, 2008. doi: 10.1158/1078-0432.CCR-14-9-COR3
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Corrections

Correction: Article on Heterogeneous Extravascular Distribution of Trastuzumab in HER2 Overexpressing Xenografts

In the article by Baker and coworkers, beginning on page 2171 of the April 1, 2008, issue of Clinical Cancer Research, Figure 3 was rendered improperly. The correct Figure 3 is shown below.


Figure 3
View larger version (72K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Heterogeneous distribution of trastuzumab through whole tumors. Tumors grown to 8 to 10 mm in diameter were dosed with 20 mg/kg trastuzumab and harvested at 3 h (A) or 26 h (B); 10 μm thick transverse sections were obtained at 1mm intervals from the tumor edge, were imaged for perfusion marker DioC7(3) (cyan), and stained for bound trastuzumab (red) and CD31 (dark blue). Examples of vessels with very little or no extravasating trastuzumab are illustrated (green arrows). Those sections obtained closer to the gross tumor edge of both the 3 h (A, left) and 26 h (B, left) show a greater proportion of tissue stained for trastuzumab than the more heterogeneous central sections (A and B, right). Quantitative analysis shows percentage of pixels positive for trastuzumab in sections at increasing distances from the tumor edge (C, left). The microregional distribution of trastuzumab as a function of distance from vasculature was analyzed on sections obtained 1 mm from tumor edge and compared with those at 4 mm; data is shown for tumors harvested at 3 h (C, middle) and 26 h (C, right) after treatment.

 




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online